Xi-Qing Chai

Xi-Qing Chai

Auto-generated profile, based on publicly available information

Xi-Qing Chai

Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
DXDong Xian-Hui
Dong Xian-Hui
GWGao Wei-Juan
Gao Wei-Juan
STShao Tie-Mei
Shao Tie-Mei
XHXie Hong-Lin
Xie Hong-Lin
BJBai Jiang-Tao
Bai Jiang-Tao
CXChai Xi-Qing
Chai Xi-Qing

1 January 2018 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
XCXi-Qing Chai
Xi-Qing Chai
YZYu Zhang
Yu Zhang
WKWei-Na Kong
Wei-Na Kong
Increasing evidence indicates that disruption of normal iron homeostasis may contribute to pathological development of Alzheimer's disease. Icariin, astragalus, and puerarin have been shown to suppress iron overload in the cerebral cortex and improve spatial learning and memory disorders in Alzheimer's disease mice, although the underlying mechanism remains unclear. In the present study, APPswe/PS1ΔE9 transgenic mice were administered icariin, astragalus, and puerarin (120, 80, and 80 mg/kg, respectively, once a day, for 3 months). Iron levels were detected by flame atomic absorption spectroscopy. Interleukin-1β, interleukin-6, and tumor necrosis factor-α levels were measured in the cerebral cortex by enzyme linked immunosorbent assay. Glutathione peroxidase and superoxide dismutase activity and malondialdehyde content were determined by colorimetry. Our results demonstrate that after treatment, iron levels and malondialdehyde content are decreased, while glutathione peroxidase and superoxide dismutase activities are increased. Further, interleukin-1β, interleukin-6, and tumor necrosis factor-α levels were reduced. These results confirm that compounds of icariin, astragalus, and puerarin may alleviate iron overload by reducing oxidative stress and the inflammatory response.

9 December 2019 in Aging
Verified
Journal Article
Open access
WYWenJun Yu
WenJun Yu
SAShengjun An
Shengjun An
TSTieMei Shao
TieMei Shao
HXHongJun Xu
HongJun Xu
HCHongXu Chen
HongXu Chen
XCXiQing Chai
XiQing Chai
Alzheimer's disease (AD), the most common cause of dementia, is a neurodegenerative disorder characterized by amyloid plaque accumulations, intracellular tangles and neuronal loss in certain brain regions. It has been shown that a disturbance of normal iron metabolism contributes to the pathophysiology of AD. However, the mechanism underlying abnormal iron load in the brain of AD patients is unclear. The frontal cortex, an important brain structure for executive function, is one of the regions affected by AD. We investigated the beneficial effects of active compounds of Epimedium, Astragaoside and Puerarin on iron metabolism in the frontal cortex of six-month-old APPswe/PS1ΔE9 (APP/PS1) double transgenic mouse, a model of AD. Treatment with the active compounds reduced cognitive and memory deficits and damaged cell ultrastructure in APP/PS1 mice. These beneficial effects were associated with changes in expression levels of iron metabolism proteins in the frontal cortex, including divalent metal transporter with iron response element (DMT1-with IRE), divalent metal transporter without iron response element (DMT1-without IRE), transferrin (TF) and transferring receptor 1 (TfR1); three release proteins including the exporter ferroportin 1 (Fpn1), ceruloplasmin (CP) and hephaestin (HEPH), one increased storage iron protein ferritin and one iron regulating hormone hepcidin. These findings suggest that the active compounds improve cognition and memory in brain neurodegenerative disorders and these beneficial effects are associated with reduced impairment of iron metabolism. This study may provide a new strategy for developing novel drugs to treat AD.

29 January 2015 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
XDXian-Hui Dong
Xian-Hui Dong
WGWei-Juan Gao
Wei-Juan Gao
WKWei-Na Kong
Wei-Na Kong
HXHong-Lin Xie
Hong-Lin Xie
YPYan Peng
Yan Peng
XCXi-Qing Chai
Xi-Qing Chai
Alzheimer's disease (AD) is a neurodegenerative brain disorder and the most common cause of dementia. New treatments for AD are required due to its increasing prevalence in aging populations. The present study evaluated the effects of the active components of Epimedium, Astragalus and Radix Puerariae on learning and memory impairment, β‑amyloid (Aβ) reduction and brain iron load in an APPswe/PS1ΔE9 transgenic mouse model of AD. Increasing evidence indicates that a disturbance of normal iron homeostasis may contribute to the pathology of AD. However, the underlying mechanisms resulting in abnormal iron load in the AD brain remain unclear. It has been hypothesized that the brain iron load is influenced by the deregulation of certain proteins associated with brain iron metabolism, including divalent metal transporter 1 (DMT1) and ferroportin 1 (FPN1). The present study investigated the effects of the active components of Epimedium, Astragalus and Radix Puerariae on the expression levels of DMT1 and FPN1. The treatment with the active components reduced cognitive deficits, inhibited Aβ plaque accumulation, reversed Aβ burden and reduced the brain iron load in AD model mice. A significant increase was observed in the levels of DMT1‑iron‑responsive element (IRE) and DMT1‑nonIRE in the hippocampus of the AD mouse brain, which was reduced by treatment with the active components. In addition, the levels of FPN1 were significantly reduced in the hippocampus of the AD mouse brain compared with those of control mice, and these levels were increased following treatment with the active components. Thus, the present study indicated that the active components of Epimedium, Astragalus and Radix Puerariae may exert a neuroprotective effect against AD by reducing iron overload in the AD brain and may provide a novel approach for the development of drugs for the treatment of AD.

1 May 2015 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
XDXian-Hui Dong
Xian-Hui Dong
JBJiang-Tao Bai
Jiang-Tao Bai
WKWei-Na Kong
Wei-Na Kong
XHXiao-Ping He
Xiao-Ping He
PYPeng Yan
Peng Yan
CLCong Liu
Cong Liu
Abnormally increased levels of iron in the brain trigger cascade amplification in Alzheimer’s disease patients, resulting in neuronal death. This study investigated whether components extracted from the Chinese herbs epimedium herb, milkvetch root and kudzuvine root could relieve the abnormal expression of iron metabolism-related protein in Alzheimer’s disease patients. An APPswe / PS1ΔE9 double transgenic mouse model of Alzheimer’s disease was used. The intragastric administration of compounds from epimedium herb, milkvetch root and kudzuvine root improved pathological alterations such as neuronal edema, increased the number of neurons, downregulated divalent metal transporter 1 expression, upregulated ferroportin 1 expression, and inhibited iron overload in the cerebral cortex of mice with Alzheimer’s disease. These compounds reduced iron overload-induced impairment of the central nervous system, indicating a new strategy for developing novel drugs for the treatment of Alzheimer’s disease.

1 December 2010
Verified
Journal Article
Closed access
YSYi-Min Sun
Yi-Min Sun
HHHong-Qiang Hao
Hong-Qiang Hao
WKWei-Na Kong
Wei-Na Kong
LLLing-Yun Liu
Ling-Yun Liu
XCXi-Qing Chai
Xi-Qing Chai